Preincubation of neutrophils with Tulopafant (RP 59227) results in a concentration-dependent decrease in chemiluminescence produced by PAF-primed cells[2].

Tulopafant (RP 59227) effectively reduces myocardial infarct size and decreases the incidence of ischemia and reperfusion-induced arrhythmias in barbital-anesthetized dogs[1]. Histological examination reveals a marked reduction in both interstitial hemorrhage and the deposition of platelets and granulocytes in capillaries of cardiac xenografts when recipient animals are pretreated with Tulopafant[1].